Stocks ended mixed Wednesday with blue-chips struggling
throughout much of today's session following weak quarterly results
for a pair of component companies on the Dow Jones Industrial
Average. But the S&P 500 and the Nasdaq Composite indices
extended their advance after better-than-expected financial
performance by Apple (
) and Biogen Idec (
) among other firms reporting results last night and today.
It was a light day for economic data, with the Mortgage Banker's
Association today reporting a surprise 0.3% rise in single-family
homes under contract, returning to positive ground following an
8.0% decline last week. Year-over-year, the purchase applications
index is down 15.0%.
Losses for Dow components Boeing (
) and McDonald's (
) following disappointing earnings results weighed on the blue-chip
index, although the Dow Industrials managed to finish today's
session above its 17,000 mark. Ongoing tension in the Middle East
and Ukraine also hindered gains, with reports shortly after the
opening bell this morning that two Ukranian jet fighters were shot
down near the same region where a Malaysia Airlines passenger jet
was shot down last week.
Federal aviation authorities in the U.S. this afternoon also
extended their moratorium on commercial flights into Israel for a
Crude oil for September delivery settled 73 cents higher at
$103.02 per barrel while August natural gas fell 1 cent to $3.76
per 1 million BTU. August gold fell $1.60 to $1.304.50 per ounce
while September silver was unchanged at $21.00 per ounce. September
copper also settled unchanged at $3.21 per pound.
Here's where the U.S. markets stood at end-of-day:
Dow Jones Industrial Average down 26.91 (-0.16%) to
S&P 500 up 3.48 (+0.18%) to 1,987.01
Nasdaq Composite Index up 17.68 (+0.40%) to 4,473.70
Hang Seng Index up 0.80%
Shanghai China Composite Index up 0.14%
FTSE 100 Index up 0.04%
(+) PBYI, Revises license pact with Pfizer (
) for its Neratinib drug candidate after the prospective cancer
treatment improved disease-free survival by 33% compared with a
placebo during testing in 2,821 women with early-stage breast
(+) DRL, Supreme Court overturns earlier ruling to side with the
bank in its dispute with the Puerto Rican government over tax
revenue owed the bank, citing "important public interest."
(+) ISRG, Turns in adjusted EPS of $3.73 per share, down from
$3.90 per share last year but crushng the Street view by $0.89 per
share. Revenue declines 12.4% year over year to $507 million,
edging out the Capital IQ consensus by $1.4 million.
(-) UIS, Reverses $20.4 mln profit last year with $12.1 mln Q2
net loss. Excluding one-time items, earns $0.11 per share, missing
Street view by $0.82 per share. Revenue slips 6% to $806 million,
lagging estimates by $21 mln.
(-) XLNX, Q1 revenue increases 6% year over year to $613 mln,
lagging Street view by $18.6 mln. Expects Q3 sales to be flat to
down 4% sequentially while analysts, on average, for expecting 5%
growth to around $644.1 mln. Q1 EPS OF $0.62 beats by $0.01.
(-) JAKK, Adjusted Q2 net loss $0.25 per share beats Capital IQ
consensus by $0.05. Revenue rises 16.9% year over year to $124.2
mln, also topping Street view by around $11.34 mln. Boosts FY14
revenue guidance by $20 mln and projected EPS by $0.05 per
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.